Education
About Us
Working with TipRanks
Follow Us
SMS Pharmaceuticals Limited (IN:SMSPHARMA)
:SMSPHARMA
SMSPHARMA Stock Chart & Stats
₹325.40
-₹5.32(-2.16%)
At close: 4:00 PM EST
₹325.40
-₹5.32(-2.16%)
Day’s Range― - ―
52-Week Range₹175.00 - ₹387.00
Previous CloseN/A
Volume71.57K
Average Volume (3M)105.50K
Market Cap
₹34.63B
Enterprise Value₹37.13B
Total Cash (Recent Filing)₹415.86M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)37.2
Beta1.66
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)2.51
Shares Outstanding93,652,030
10 Day Avg. Volume15,241
30 Day Avg. Volume105,503
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.91
Price to Sales (P/S)2.38
P/FCF Ratio-31.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth across 2020–2025 indicates expanding demand and market presence in APIs. Reliable revenue expansion supports scale economics, funds capacity investments and R&D, and improves the firm's ability to absorb price or input shocks over multiple quarters.
Moderate Leverage And Strong Equity BackingA moderate debt profile combined with solid equity backing provides financial flexibility for capex and working capital. This structure lowers refinancing and solvency risk, enabling the company to pursue capacity expansion or weather cyclical API demand without excessive interest strain.
Positive Operating Cash FlowConsistent positive operating cash flow shows core API operations generate real cash even with FCF swings. Reliable operational cash supports supplier payments, reinvestment in manufacturing capacity and working capital, reducing dependence on external financing over the medium term.
Bears Say
Net Income Volatility / 2023 LossA meaningful net income decline and a negative margin in 2023 reveal earnings instability. Persistent volatility undermines predictability of returns, can constrain capital allocation to growth or dividends, and signals structural or market pressures that may persist across multiple quarters.
Inconsistent Free Cash FlowMaterial FCF swings, including negative years, create funding uncertainty for capex and working capital. This increases the likelihood of relying on external financing during downturns, raising financing costs or dilution and limiting the firm's ability to consistently invest in durable capacity upgrades.
Margin And Cost-management FluctuationsFluctuating gross margins and signs of cost-control issues point to operational inefficiencies or input-price exposure. Margin instability erodes competitive advantage in API markets and reduces resilience to pricing pressure unless addressed through sustained process or procurement improvements.
SMS Pharmaceuticals Limited News
SMSPHARMA FAQ
What was SMS Pharmaceuticals Limited’s price range in the past 12 months?
SMS Pharmaceuticals Limited lowest stock price was ₹175.00 and its highest was ₹387.00 in the past 12 months.
What is SMS Pharmaceuticals Limited’s market cap?
SMS Pharmaceuticals Limited’s market cap is ₹34.63B.
When is SMS Pharmaceuticals Limited’s upcoming earnings report date?
SMS Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 101 days.
How were SMS Pharmaceuticals Limited’s earnings last quarter?
SMS Pharmaceuticals Limited released its earnings results on Feb 07, 2026. The company reported ₹2.506 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.506.
Is SMS Pharmaceuticals Limited overvalued?
According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Overvalued.
Does SMS Pharmaceuticals Limited pay dividends?
SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.13%. See more information on SMS Pharmaceuticals Limited dividends here
What is SMS Pharmaceuticals Limited’s EPS estimate?
SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Pharmaceuticals Limited have?
SMS Pharmaceuticals Limited has 93,652,030 shares outstanding.
What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?
SMS Pharmaceuticals Limited reported an EPS of ₹2.506 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.745%.
Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:SMSPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.
Technical Analysis
Bajaj Healthcare Ltd
―
Indoco Remedies Limited
―
Medi Assist Healthcare Services Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―